NCT01911325 - Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Squamous Non-small Cell Lung Cancer

Interventions

DRUG

Buparlisib

DRUG

Buparlisib matching placebo

DRUG

Docetaxel

Trial Locations (16)

6000

Novartis Investigative Site, Charleroi

7000

Novartis Investigative Site, Mons

20900

Novartis Investigative Site, Monza

23502

Virginia Oncology Associates Virginia Oncology Assoc. (2), Norfolk

33612

H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt, Tampa

44805

Novartis Investigative Site, Saint-Herblain

55131

Novartis Investigative Site, Mainz

60590

Novartis Investigative Site, Frankfurt

69120

Novartis Investigative Site, Heidelberg

72703

Highlands Oncology Group SC-1, Fayetteville

94000

Novartis Investigative Site, Créteil

01608

Reliant Medical Group Reliant Medical Group, Worcester

05505

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

08036

Novartis Investigative Site, Barcelona

171 76

Novartis Investigative Site, Stockholm